佩尔索斯治疗公司获得Xepi乳膏在美国的独家营销权Pelthos Therapeutics Secures Exclusive U.S. Marketing Rights for Xepi Cream

动脉网2025-11-10

by GOAI由GOAI生成Share To分享到Pelthos Therapeutics has acquired the exclusive rights to market Xepi (ozenoxacin) Cream, 1%, in the United States. The product is a non-fluorinated quinolone antimicrobial ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2582381023?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-11-10 18:09","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2582381023","market":"us","top_or_hot":-1,"title":"佩尔索斯治疗公司获得Xepi乳膏在美国的独家营销权Pelthos Therapeutics Secures Exclusive U.S. Marketing Rights for Xepi Cream","media":"动脉网","content":"<div>\n<p>by GOAI由GOAI生成Share To分享到Pelthos Therapeutics has acquired the exclusive rights to market Xepi (ozenoxacin) Cream, 1%, in the United States. The product is a non-fluorinated quinolone antimicrobial ...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111018112494fb2a80&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>佩尔索斯治疗公司获得Xepi乳膏在美国的独家营销权Pelthos Therapeutics Secures Exclusive U.S. Marketing Rights for Xepi Cream</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n佩尔索斯治疗公司获得Xepi乳膏在美国的独家营销权Pelthos Therapeutics Secures Exclusive U.S. Marketing Rights for Xepi Cream\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-10 18:09 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111018112494fb2a80&s=b><strong>动脉网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>by GOAI由GOAI生成Share To分享到Pelthos Therapeutics has acquired the exclusive rights to market Xepi (ozenoxacin) Cream, 1%, in the United States. The product is a non-fluorinated quinolone antimicrobial ...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111018112494fb2a80&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PTHS","symbol_name":"PELTHOS THERAPEUTICS INC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111018112494fb2a80&s=b","article_id":"2582381023","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111018112494fb2a80&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2582381023","pubTimestamp":1762769340,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"此协议授予Pelthos在美国境内对Xepi的分销和商业化的控制权。Xepi Cream, which contains 1% ozenoxacin, is used as an antimicrobial treatment for skin infections. The acquisition involves transferring marketing rights from Biofrontera and Ferrer to Pelthos Therapeutics, allowing the company to oversee its availability and promotion across the country.含有1%奥泽诺沙星的Xepi乳膏被用作皮肤感染的抗菌治疗。此次收购涉及将Xepi的营销权从Biofrontera和Ferrer转移至Pelthos Therapeutics，使该公司能够在全国范围内监督其供应与推广。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"PTHS":"PELTHOS THERAPEUTICS INC","BK4007":"制药","BK4539":"次新股","LENZ":"Therapeutics","BK4139":"生物科技"},"translate_title":"Pelthos Therapeutics Secures Exclusive U.S. Marketing Rights for Xepi Cream","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PTHS":0.9,"LENZ":1.5},"content_text":"by GOAI由GOAI生成Share To分享到Pelthos Therapeutics has acquired the exclusive rights to market Xepi (ozenoxacin) Cream, 1%, in the United States. The product is a non-fluorinated quinolone antimicrobial cream designed for topical use. This agreement grants Pelthos control over the distribution and commercialization of Xepi within the U.S.Pelthos Therapeutics已获得在美国市场销售1% Xepi（奥泽诺沙星）乳膏的独家权利。该产品是一种用于局部使用的非氟喹诺酮类抗菌药膏。此协议授予Pelthos在美国境内对Xepi的分销和商业化的控制权。market..市场。。Xepi Cream, which contains 1% ozenoxacin, is used as an antimicrobial treatment for skin infections. The acquisition involves transferring marketing rights from Biofrontera and Ferrer to Pelthos Therapeutics, allowing the company to oversee its availability and promotion across the country.含有1%奥泽诺沙星的Xepi乳膏被用作皮肤感染的抗菌治疗。此次收购涉及将Xepi的营销权从Biofrontera和Ferrer转移至Pelthos Therapeutics，使该公司能够在全国范围内监督其供应与推广。Newsflash | Powered by GeneOnline AI新闻快讯 | 由GeneOnline AI提供支持Source: GO-AI-ne1来源：GO-AI-ne1For any suggestion and feedback, please contact us.如有任何建议和反馈，请联系我们。Date: November 10, 2025日期：2025年11月10日Related posts:相关文章：Generic Drug Makers Optimize Supply Chains with Real-Time Monitoring via AI and IoT.通用药物制造商通过人工智能和物联网进行实时监控来优化供应链。Biopharma Industry Growth Drives Demand for Packaging That Ensures Stability and Sterility生物制药行业的增长推动了对确保稳定性和无菌性的包装的需求。Candidate Drug Found to Boost Protective Protein and Improve Memory in Mice with Alzheimer’s Disease阿尔茨海默病小鼠体内发现可增强保护性蛋白并改善记忆的候选药物Eight Horror Films to Premiere on Major Streaming Platforms in October 20252025年10月，八大恐怖电影将在主流流媒体平台首映。©www.geneonline.com All rights reserved. Collaborate with us:©www.geneonline.com 保留所有权利。与我们合作：[email protected]电子邮件地址Author作者GOAIGOAIRelated Post相关文章News Flash新闻快讯SanegeneBio and Eli Lilly Partner to Develop RNAi Therapeutics for Metabolic Diseases赛诺基因生物与礼来合作开发针对代谢疾病的RNAi疗法2025-11-102025年11月10日","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2582381023","isCrawlerRequest":true}